Laidlaw Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

October 3, 2024 2:14 PM EDT Send to a Friend
Laidlaw analyst Yale Jen reiterated a Buy rating and $11.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX).The analyst commented, "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login